HIGHLIGHTS
- who: Andreas Wollenberg from the (UNIVERSITY) have published the paper: Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence, in the Journal: (JOURNAL) of December/31,/2019
- what: The authors examine the existing data showing the use of omalizumab the only biologic anti-IgE therapy available in clinical use plasma apheresis and a combination of both therapeutic approaches for the treatment of AD. For the preparation of this article, an Ovid literature search was conducted with Medline, Embase, and Biosys as the databases, on anti-IgE treatment in AD from January 2002 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.